Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Hemoglobinopathy Treatment Market Size Growth Rate by Type (2014-2025)
1.4.2 Hydroxyurea
1.4.3 Glutamine
1.4.4 Zynteglo
1.4.5 Other
1.5 Market by Application
1.5.1 Global Hemoglobinopathy Treatment Market Share by Application (2019-2025)
1.5.2 Sickle Cell Diseases
1.5.3 Thalassemia
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Hemoglobinopathy Treatment Market Size
2.2 Hemoglobinopathy Treatment Growth Trends by Regions
2.2.1 Hemoglobinopathy Treatment Market Size by Regions (2019-2025)
2.2.2 Hemoglobinopathy Treatment Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
3 Market Share by Key Players
3.1 Hemoglobinopathy Treatment Market Size by by Players
3.1.1 Global Hemoglobinopathy Treatment Revenue by by Players (2014-2019)
3.1.2 Global Hemoglobinopathy Treatment Revenue Market Share by by Players (2014-2019)
3.1.3 Global Hemoglobinopathy Treatment Market Concentration Ratio (CR5 and HHI)
3.2 Hemoglobinopathy Treatment Key Players Head office and Area Served
3.3 Key Players Hemoglobinopathy Treatment Product/Solution/Service
3.4 Date of Enter into Hemoglobinopathy Treatment Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
4.1 Global Hemoglobinopathy Treatment Market Size by Type (2014-2019)
4.2 Global Hemoglobinopathy Treatment Market Size by Application (2014-2019)
5 North America
5.1 North America Hemoglobinopathy Treatment Market Size (2014-2019)
5.2 Hemoglobinopathy Treatment Key Players in North America
5.3 North America Hemoglobinopathy Treatment Market Size by Type
5.4 North America Hemoglobinopathy Treatment Market Size by Application
6 Europe
6.1 Europe Hemoglobinopathy Treatment Market Size (2014-2019)
6.2 Hemoglobinopathy Treatment Key Players in Europe
6.3 Europe Hemoglobinopathy Treatment Market Size by Type
6.4 Europe Hemoglobinopathy Treatment Market Size by Application
7 China
7.1 China Hemoglobinopathy Treatment Market Size (2014-2019)
7.2 Hemoglobinopathy Treatment Key Players in China
7.3 China Hemoglobinopathy Treatment Market Size by Type
7.4 China Hemoglobinopathy Treatment Market Size by Application
8 Japan
8.1 Japan Hemoglobinopathy Treatment Market Size (2014-2019)
8.2 Hemoglobinopathy Treatment Key Players in Japan
8.3 Japan Hemoglobinopathy Treatment Market Size by Type
8.4 Japan Hemoglobinopathy Treatment Market Size by Application
9 Southeast Asia
9.1 Southeast Asia Hemoglobinopathy Treatment Market Size (2014-2019)
9.2 Hemoglobinopathy Treatment Key Players in Southeast Asia
9.3 Southeast Asia Hemoglobinopathy Treatment Market Size by Type
9.4 Southeast Asia Hemoglobinopathy Treatment Market Size by Application
10 India
10.1 India Hemoglobinopathy Treatment Market Size (2014-2019)
10.2 Hemoglobinopathy Treatment Key Players in India
10.3 India Hemoglobinopathy Treatment Market Size by Type
10.4 India Hemoglobinopathy Treatment Market Size by Application
11 Central & South America
11.1 Central & South America Hemoglobinopathy Treatment Market Size (2014-2019)
11.2 Hemoglobinopathy Treatment Key Players in Central & South America
11.3 Central & South America Hemoglobinopathy Treatment Market Size by Type
11.4 Central & South America Hemoglobinopathy Treatment Market Size by Application
12 International Players Profiles
12.1 Novartis
12.1.1 Novartis Company Details
12.1.2 Company Description and Business Overview
12.1.3 Hemoglobinopathy Treatment Introduction
12.1.4 Novartis Revenue in Hemoglobinopathy Treatment Business (2014-2019))
12.1.5 Novartis Recent Development
12.2 AstraZeneca
12.2.1 AstraZeneca Company Details
12.2.2 Company Description and Business Overview
12.2.3 Hemoglobinopathy Treatment Introduction
12.2.4 AstraZeneca Revenue in Hemoglobinopathy Treatment Business (2014-2019)
12.2.5 AstraZeneca Recent Development
12.3 Bluebird
12.3.1 Bluebird Company Details
12.3.2 Company Description and Business Overview
12.3.3 Hemoglobinopathy Treatment Introduction
12.3.4 Bluebird Revenue in Hemoglobinopathy Treatment Business (2014-2019)
12.3.5 Bluebird Recent Development
12.4 Bristol-Myers Squibb
12.4.1 Bristol-Myers Squibb Company Details
12.4.2 Company Description and Business Overview
12.4.3 Hemoglobinopathy Treatment Introduction
12.4.4 Bristol-Myers Squibb Revenue in Hemoglobinopathy Treatment Business (2014-2019)
12.4.5 Bristol-Myers Squibb Recent Development
12.5 Emmaus Medical
12.5.1 Emmaus Medical Company Details
12.5.2 Company Description and Business Overview
12.5.3 Hemoglobinopathy Treatment Introduction
12.5.4 Emmaus Medical Revenue in Hemoglobinopathy Treatment Business (2014-2019)
12.5.5 Emmaus Medical Recent Development
12.6 Acceleron Pharma
12.6.1 Acceleron Pharma Company Details
12.6.2 Company Description and Business Overview
12.6.3 Hemoglobinopathy Treatment Introduction
12.6.4 Acceleron Pharma Revenue in Hemoglobinopathy Treatment Business (2014-2019)
12.6.5 Acceleron Pharma Recent Development
12.7 HemaQuest Pharmaceuticals
12.7.1 HemaQuest Pharmaceuticals Company Details
12.7.2 Company Description and Business Overview
12.7.3 Hemoglobinopathy Treatment Introduction
12.7.4 HemaQuest Pharmaceuticals Revenue in Hemoglobinopathy Treatment Business (2014-2019)
12.7.5 HemaQuest Pharmaceuticals Recent Development
12.8 Eli Lilly and Company
12.8.1 Eli Lilly and Company Company Details
12.8.2 Company Description and Business Overview
12.8.3 Hemoglobinopathy Treatment Introduction
12.8.4 Eli Lilly and Company Revenue in Hemoglobinopathy Treatment Business (2014-2019)
12.8.5 Eli Lilly and Company Recent Development
12.9 Celgene
12.9.1 Celgene Company Details
12.9.2 Company Description and Business Overview
12.9.3 Hemoglobinopathy Treatment Introduction
12.9.4 Celgene Revenue in Hemoglobinopathy Treatment Business (2014-2019)
12.9.5 Celgene Recent Development
13 Market Forecast 2019-2025
13.1 Market Size Forecast by Product (2019-2025)
13.2 Market Size Forecast by Application (2019-2025)
13.3 Market Size Forecast by Regions
13.4 North America
13.5 Europe
13.6 China
13.7 Japan
13.8 Southeast Asia
13.9 India
13.10 Central & South America
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details
【掲載企業】
Novartis、AstraZeneca、Bluebird、Bristol-Myers Squibb、Emmaus Medical、Acceleron Pharma、HemaQuest Pharmaceuticals、Eli Lilly and Company、Celgene
【免責事項】
https://www.globalresearch.jp/disclaimer